Somewhere right now, someone has an idea for a game. They know exactly what it would feel like to play. They just don’t know how to build it. Today, that changes. Twenty years ago, Roblox launched ...

Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ruled that the company did not violate its agreement with Beam ...

A Midtown high-rise was dramatically evacuated during the Tuesday morning rush when massive beams in the under-construction building started buckling — prompting several floors to cave in and sending ...

Earnings Miss Sparks Concern: Social media chatter highlights how Roblox's latest quarterly results disappointed investors, with daily active users dropping notably and bookings growth falling short ...

Beam (beam.cloud) is a serverless GPU and Python cloud-runtime platform. You write ordinary Python, decorate it, and Beam deploys it as a web endpoint, a task queue, a scheduled job, or a secure ...

is a senior editor and founding member of The Verge who covers gadgets, games, and toys. He spent 15 years editing the likes of CNET, Gizmodo, and Engadget. They tell me no one outside Google has seen ...

ROBLOX ($RBLX) posted quarterly earnings results for Q1 2026 on Thursday, April 30th. The company reported earnings of -$0.29 per share, beating estimates of -$0.42 ...

Scientists at MIT say they made a finding in optical physics that could enable a new bioimaging method that’s faster and higher-resolution than existing technology. They discovered that, under the ...

Roblox is launching a brand-new subscription tier, and it comes with some genuinely useful perks. While the new features and the changes to Roblox Premium can feel quite overwhelming if you don't go ...

As conflict escalates following the US and Israeli attacks on Iran, and Iran’s subsequent retaliatory strikes, reports have emerged that Israel may have used laser weapons to shoot down rockets fired ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate. The agreement, ...